16th CEO Survey: Pharmaceuticals and Life Sciences findings
The 16th Annual Global CEO Survey was launched January 22, 2013 in Davos, Switzerland. This year we interviewed over 1,300 of the world’s chief executives in over 60 countries, including 120 Canadian CEOs. In this year’s survey Dealing with disruption: adapting to survive, for business leaders across the world, ‘expect the unexpected’ has become the mantra. Organizations need to develop a new characteristic: resilience. They need the ability to ride out the immediate impact of shocks, with a long-term capacity to adapt to constantly-changing conditions.
This year, we interviewed 90 pharmaceuticals and life sciences CEOs in 37 countries. We also spoke in-depth with Yasuchika Hasegawa of Takeda. Pharmaceuticals and life sciences execs say they’re balancing the needs of patients and society while walking the regulatory high-wire in this year’s 16th Annual Global CEO Survey.
Read the full pharmaceutical and life sciences industry summary.
Global Healthcare Deals Quarterly: Weaker 2012 M&A pace reflects US slowdown - Third Quarter 2012
The third quarter of 2012 saw a slower global deals pace. Contributing factors included overhangs related to US healthcare and fiscal policy. However, looking ahead, we find support for an improving M&A outlook as healthcare companies take advantage of historically low interest rates and highly receptive capital markets to introduce or expand international revenue streams in an effort to maintain or bolster financial health. In particular, we found an important shift in sentiment towards globalization emerging among the historically insular payers and providers. Read more about notable market developments.